Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo
on markers of cardiac injury, structure, and function among patients who recovered from acute
COVID-19 infection.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan